Clinical trial
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head…
NCT00460265 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00460265 |
|---|---|
| Title | Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer |
| Official title | A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Acronym | SPECTRUM |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Recurrent and/or Metastatic Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | ARM 2, ARM 1 |
| Enrollment | 658 |
| Start date | May 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2012 |
| First posted | Apr 13, 2007 |
| Last update posted | Mar 7, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: